Company intelligence / Profile preview

Joseph Hazelton

Jupiter, Florida, United Statesen.wikipedia.org ↗

Ownership: Private
Development stage: Other

Overview

Dyadic has achieved commercial validation through partnerships such as with Proliant Health and Biologicals for recombinant human albumin and a joint venture with Fermbox Bio launching EN3ZYME. The company’s C1 and Dapibus™ platforms enable large-scale production of recombinant proteins. While the main focus is now on ancillary protein products for non-pharmaceutical applications (life sciences, nutrition), some legacy pharmaceutical/biopharma programs remain active with at least one program having completed Phase 1 clinical trials in 2023.

Therapeutic areas: Other
Modalities: Recombinant proteinBiologicEnzyme
Industry: Biotech

Partnerships

Proliant Health and Biologicals (recombinant human albumin)Fermbox Bio (EN3ZYME joint venture)

Beyond the preview

Go deeper on Joseph Hazelton.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Joseph Hazelton.

Explore the full profile